Artiva Biotherapeutics (ARTV) Free Cash Flow (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Free Cash Flow for 4 consecutive years, with -$21.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow fell 2.26% year-over-year to -$21.2 million; the TTM figure through Mar 2026 stood at -$77.5 million (down 27.58% YoY), while the FY2025 annual figure was -$77.0 million, down 39.76% from the prior year.
• Free Cash Flow slipped to -$21.2 million in Q1 2026 per ARTV's latest filing, from -$14.5 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$7.9 million in Q4 2023 and bottomed at -$22.4 million in Q2 2025.
• Historically, Free Cash Flow has averaged -$15.9 million across 4 years, with a median of -$14.8 million in 2024.
• On a YoY basis, Free Cash Flow climbed as much as 17.85% in 2024 and fell as far as 87.02% in 2024.
• Artiva Biotherapeutics' Free Cash Flow stood at -$7.9 million in 2023, then slumped by 87.02% to -$14.8 million in 2024, then increased by 1.76% to -$14.5 million in 2025, then tumbled by 45.75% to -$21.2 million in 2026.
• Business Quant data shows ARTV's Free Cash Flow at -$21.2 million in Q1 2026, -$14.5 million in Q4 2025, and -$19.3 million in Q3 2025.